For years, doctors, scientists, and ethicists have debated whether people will benefit from decoding their DNA, the three billion letters of the genome that spell out traits and predisposition to disease. Now, that complicated conversation is moving to a new venue: the newborn nursery. Alan Beggs, the Sir Edwin and Lady Manton Professor of Pediatrics at Boston Children’s Hospital and Robert Green, HMS lecturer on medicine at Brigham and Women’s Hospital, designed a trial to measure benefits and risks of newborn sequencing.
Read full article (subscription required)
